ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Why We Must Aggressively Treat Risk Factors Before Antiplatelets"
Episode Synopsis
‘It's that yin and yang or balance back and forth between preventing thrombotic events but also trying to minimize bleeding events.’ said Dr. David J. Moliterno in a conversation with Dr Vishal Rastogi at the annual India Live 2024.
Here are the top 5 takeaways:
1. Antiplatelet therapies are crucial post-stenting to prevent clots and manage risks.
2. Aggressive risk factor management reduces the need for intensive therapy.
3. Balance the potency and duration of antiplatelet drugs for optimal therapy.
4. Rivaroxaban shows benefits beyond atrial fibrillation in ACS and peripheral disease.
5. Management of dual antithrombotic therapy is critical for patients with high bleeding risk.
Dr. David J. Moliterno is the editor-in-chief of JACC: Cardiovascular Interventions and a Professor of Medicine in the Department of Internal Medicine at the University of Kentucky.
Dr. Moliterno completed his medical degree at the Medical College of Virginia and underwent residency training at Vanderbilt University Medical Center, establishing a strong foundation for his career.
With over 400 publications to his name, Dr. Moliterno is recognized for his extensive contributions to cardiology literature and has edited eight textbooks on the subject. His expertise has led him to serve as a visiting professor or lecturer in more than 30 countries, reflecting his global influence in cardiology.
LinkedIn: https://www.linkedin.com/in/david-moliterno-8a06422b6/
Website: https://www.jacc.org/journal/interventions/editor-in-chief-biography
Dr. Vishal Rastogi is a highly regarded Interventional Cardiologist based in Delhi, currently serving as the Director of Interventional Cardiology and Head of the Advanced Heart Failure Program at Fortis Escorts Heart Institute. With over 20 years of experience, he specializes in complex coronary interventions, including procedures such as Rotablation, carotid interventions, and percutaneous aortic valve implantation. Dr. Rastogi is particularly noted for his expertise in implanting the Impella Left Ventricular Assist Device, making him one of the most experienced practitioners in India for this critical procedure. He is also a national proctor for advanced coronary imaging techniques and dedicated bifurcation stents, playing an essential role in training other medical professionals.
Academically, Dr. Rastogi holds an MBBS and MD from Banaras Hindu University and a DM in Cardiology from Maulana Azad Medical College. His contributions extend to research, where he serves as the principal investigator for various interventional and heart failure trials. Additionally, he is a member of professional organizations such as the Cardiological Society of India and the Heart Failure Association of the European Society of Cardiology.
LinkedIn: https://www.linkedin.com/in/vishal-rastogi-88145042/?originalSubdomain=in
Website: https://www.fortishealthcare.com/doctors/dr-vishal-rastogi-737
Here are the top 5 takeaways:
1. Antiplatelet therapies are crucial post-stenting to prevent clots and manage risks.
2. Aggressive risk factor management reduces the need for intensive therapy.
3. Balance the potency and duration of antiplatelet drugs for optimal therapy.
4. Rivaroxaban shows benefits beyond atrial fibrillation in ACS and peripheral disease.
5. Management of dual antithrombotic therapy is critical for patients with high bleeding risk.
Dr. David J. Moliterno is the editor-in-chief of JACC: Cardiovascular Interventions and a Professor of Medicine in the Department of Internal Medicine at the University of Kentucky.
Dr. Moliterno completed his medical degree at the Medical College of Virginia and underwent residency training at Vanderbilt University Medical Center, establishing a strong foundation for his career.
With over 400 publications to his name, Dr. Moliterno is recognized for his extensive contributions to cardiology literature and has edited eight textbooks on the subject. His expertise has led him to serve as a visiting professor or lecturer in more than 30 countries, reflecting his global influence in cardiology.
LinkedIn: https://www.linkedin.com/in/david-moliterno-8a06422b6/
Website: https://www.jacc.org/journal/interventions/editor-in-chief-biography
Dr. Vishal Rastogi is a highly regarded Interventional Cardiologist based in Delhi, currently serving as the Director of Interventional Cardiology and Head of the Advanced Heart Failure Program at Fortis Escorts Heart Institute. With over 20 years of experience, he specializes in complex coronary interventions, including procedures such as Rotablation, carotid interventions, and percutaneous aortic valve implantation. Dr. Rastogi is particularly noted for his expertise in implanting the Impella Left Ventricular Assist Device, making him one of the most experienced practitioners in India for this critical procedure. He is also a national proctor for advanced coronary imaging techniques and dedicated bifurcation stents, playing an essential role in training other medical professionals.
Academically, Dr. Rastogi holds an MBBS and MD from Banaras Hindu University and a DM in Cardiology from Maulana Azad Medical College. His contributions extend to research, where he serves as the principal investigator for various interventional and heart failure trials. Additionally, he is a member of professional organizations such as the Cardiological Society of India and the Heart Failure Association of the European Society of Cardiology.
LinkedIn: https://www.linkedin.com/in/vishal-rastogi-88145042/?originalSubdomain=in
Website: https://www.fortishealthcare.com/doctors/dr-vishal-rastogi-737
In God we trust